Mazdutide vs Triptorelin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
MazdutideSexual Health & Libido
Triptorelin- Summary
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with 100x the potency of native GnRH. An FDA-approved drug (Trelstar) for prostate cancer and precocious puberty, it is also used in post-cycle therapy (PCT) to rapidly restart the hypothalamic-pituitary-gonadal (HPG) axis after anabolic steroid suppression.
- Half-Life
- ~7 days
- Depot forms: weeks to months; aqueous: 6-8 hours
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- 100 mcg
- Frequency
- Once weekly
- Single injection
- Key Benefits
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Rapid HPG axis restart after steroid use
- Single-injection PCT protocol possible
- Massively elevates LH and FSH via flare effect
- Restores endogenous testosterone faster than traditional PCT
- FDA-approved for established medical uses
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Initial testosterone flare (intended)
- Injection site reactions
- Hot flashes (with chronic use)
- Decreased libido (chronic dosing)
- Stacks With
- —
- —